Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Patients With Candidemia and/or Invasive Candidiasis Caused by Candida Auris

Next Previous
Search
Trial Profile

An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Patients With Candidemia and/or Invasive Candidiasis Caused by Candida Auris

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosmanogepix (Primary) ; Fosmanogepix (Primary)
  • Indications Candidaemia; Invasive candidiasis
  • Focus Therapeutic Use
  • Acronyms APEX
  • Sponsors Amplyx Pharmaceuticals; Pfizer

    • Most Recent Events

    • 06 Apr 2023 Results from a Phase 2 trial assessing FMGX safety and efficacy for treatment of candidemia and/or invasive candidiasis caused by Candida auris published in the Antimicrobial Agents and Chemotherapy
    • 31 Mar 2023 Status changed from discontinued to completed.
    • 05 Mar 2021 Status changed from active, no longer recruiting to discontinued as the result of the impact of COVID-19 on trial-related activities.The study was not terminated due to any safety issues or concerns. The objectives of the study were successfully met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top